An interventional study of Valence-Specific Ecological Momentary Intervention in Depressive Disorder, Major, Persistent Depressive Disorder and Healthy, sponsored by Heidelberg University. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-27.
Sponsored by Heidelberg University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Depressive Disorder, Major with a site in Germany — 26 open to participants now, 27 under way, 5 of them phase 3. Depressive Disorder, Major · Germany.
Among the 164 studies in Depressive Disorder, Major with a site in Germany, this one is the 72nd largest by planned enrollment of the 150 interventional ones that give a count, is one of 10 that started in 2024, is one of 53 with no phase, reaches primary completion later than 2 of the 26 other live ones, and was the 141st registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →26 of the 164 studies in Depressive Disorder, Major with a site in Germany are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Germany, United States, Australia and 12 more countries
Ages 18–75
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Sites in Germany, Italy, Spain
Ages up to 45 · Healthy volunteers
University of Regensburg · Sites in Germany
Ages 18–70
Eli Lilly and Company · Sites in Germany, United States, Australia and 12 more countries
Ages 18–75
Cybin IRL Limited · Sites in Germany, United States, Australia and 5 more countries
Ages 18–85
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 29 · Phase 3 51 · Phase 4 10
First in 1998; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 176 across the 150 interventional studies, 104 across the 13 observational. Of the 124 that completed or were terminated, 43 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 164 have an industry lead sponsor. The 10 most frequent:
Heidelberg University is the lead sponsor of 287 studies on the registry; 18 are open to participants now.
Heidelberg University has 2 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
10 of the studies in Depressive Disorder, Major with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
| NCT06793397Phase 3Cybin IRL LimitedA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | 2027-06-07 |
| NCT06389175University of BonnNon-invasive Vagus Nerve Stimulation as a Tool to Modulate Stomach-Brain Coupling in Depression | 2026-12 |
| NCT07197138Max-Planck-Institute of PsychiatryIMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition | 2027-01 |
| NCT07065240Seaport TherapeuticsA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 164 studies in Depressive Disorder, Major with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This two-armed randomized controlled trial aims to investigate the effectiveness of an emotion regulation intervention in individuals with and without depressive disorders. The study encompasses participants diagnosed with mild to moderate major depression or persistent depressive disorder and healthy controls without a current depressive disorder.
Participants will be randomly assigned to either the intervention group, receiving a valence-specific emotion regulation intervention in daily life, or a monitoring-only control group. The valence-specific intervention supports the implementation of different emotion regulation strategies based on whether a person is experiencing mainly positive or negative emotions. In contrast, participants in the control group will solely monitor their positive and negative emotions and the strategies used to regulate them.
Outcome measures include emotion regulation ability, self-efficacy, and strategy use, depressive symptoms, positive and negative affect, and emotion beliefs (controllability, usefulness).
A second aim of the study is to compare beliefs about positive emotions and strategies to regulate them between individuals with and without current depressive disorders. Furthermore, the investigators aim to examine why individuals might choose unfavorable emotion regulation strategies even when feeling good. Therefore, another research question is, how emotion beliefs might explain emotion regulation strategy choice.
Background:
Affective disorders, such as depression, have been consistently associated with deficiencies not only in the regulation of negative emotions but also in the maintenance and upregulation of positive emotions. However, the mechanisms underlying emotion regulation deficits in depressive disorders remain inadequately understood. Recently, there has been a growing interest in the role of beliefs about emotions as factors contributing to emotion regulation deficits in psychopathology. In light of this, this study seeks to explore potential differences in beliefs about positive (and negative) emotions between individuals with and without current depressive disorders. Another aim of this study is to examine how these individual differences in emotion beliefs predict the selection of emotion regulation strategies in daily life, particularly in the context of positive emotions.
Given the pivotal role that deficits in emotion regulation play in the onset and persistence of depressive disorders, this study aims to investigate whether an ecological momentary intervention, addressing both positive and negative emotion regulation, can effectively improve emotion regulation processes. Recent research suggests that distinct emotion regulation strategies may be effective for positive versus negative emotion regulation. Consequently, this study aims to evaluate the effectiveness of a smartphone-based, valence-specific emotion regulation intervention in individuals with and without current depressive disorders.
Method:
This study will enlist participants aged between 18 and 65, diagnosed with mild to moderate major depression or persistent depressive disorder, as well as healthy controls without a current depressive disorder. Individuals presenting with a current severe substance use disorder, acute suicidality, an ongoing severe major depressive episode, a history of bipolar disorder, or lifetime psychotic disorders are precluded from participation in both groups. Additional exclusion criteria for participation within the control cohort encompass (a) occurrence of a major depressive episode in the preceding 12 months, (b) history of severe major depressive episodes, (c) diagnosis of recurrent depressive disorder or history of persistent depressive disorder, and (d) ongoing treatment modalities related to a depressive episode, including psychotherapy or pharmacotherapy.
Participants will undergo baseline questionnaires before completing four daily smartphone-based assessments over seven consecutive days, evaluating their emotion beliefs, emotion regulation, and emotional outcomes. Participants will be randomly assigned to either the intervention or the monitoring-only control group. Following a four-day break, participants in the intervention group will receive a valence-specific ecological momentary intervention targeting emotion regulation in daily life. During this period, participants will report their emotional experiences twice daily and will be supported in implementing either reappraisal or savoring strategies based on the valence of their current predominant emotion. Participants in the control group will be instructed to complete two daily assessments, monitoring their emotions and the strategies used to regulate them. After an additional four-day break, participants will be invited to complete post-assessment questionnaires capturing emotion regulation ability, self-efficacy and strategy use, depressive symptoms, emotion beliefs (controllability, usefulness), and another week of ecological momentary assessment (four per day), encompassing, among other variables, the use of emotion regulation strategies and the experience of positive and negative emotions.
Hypotheses:
The valence-specific intervention is hypothesized to enhance emotion regulation ability and self-efficacy, emotional outcomes (depressive symptoms, positive and negative affect), and emotion beliefs (controllability, usefulness) and to increase the application of reappraisal in negative and savoring in positive emotional contexts in daily life.
The investigators hypothesize that individuals with current depressive disorders will report more unfavorable beliefs about emotions and higher use of strategies associated with dampening positive emotions compared to controls at baseline.
Furthermore, the investigators expect that unfavorable beliefs about positive emotions at baseline (i.e., assuming that positive emotions are harmful) may predict the selection of dampening strategies in the context of positive emotions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For individuals in the clinical group with current depressive disorders:
Exclusion Criteria:
For the control group, additional exclusion criteria include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants complete a valence-specific ecological momentary intervention twice daily over 14 consecutive days. The ecological momentary intervention is presented as the "Positive Everyday Affect Knowledge" (PEAK) diary and includes valence-specific emotion regulation strategy instructions. Participants receive reminders to complete surveys on their strongest emotions since the last assessment. Depending on the valence of this emotion, they receive instructions on how to use the strategy savoring (for positive emotions) or reappraisal (for negative emotions).
Behavioral: Valence-Specific Ecological Momentary Intervention
Participants complete a valence-specific ecological momentary assessment twice daily over 14 consecutive days. The ecological momentary assessment is presented as the "Positive Everyday Affect Knowledge" (PEAK) diary, and only involves monitoring participants' emotional experiences and regulation. Participants receive reminders to complete surveys on their strongest emotions since the last assessment. Depending on the valence of this emotion (positive versus negative), they are asked about their emotion regulation strategies.
The ecological momentary intervention is designed to enhance participants ability to select and effectively implement emotion regulation strategies fitting to the valence of their current emotions. Specifically, the intervention instructs participants to use the strategy of savoring to amplify their positive emotions, fostering an appreciation for the present moment. Conversely, for the attenuation of negative emotions, the intervention advocates to use the strategy of reappraisal, encouraging participants to reinterpret adverse situations in a more positive or neutral way, thus reducing their emotional impact. This targeted approach ensures that the emotion regulation strategies are not only effective but also contextually appropriate.
Emotion Regulation Ability (Positive, Negative Emotions)
The Perth Emotion Regulation Competency Inventory (PERCI; Preece al., 2021) consists of 32 items, rated on a 7-point scale (1 = strongly disagree, 4 = neither agree nor disagree, 7 = strongly agree) and measures people's ability to regulate their positive and negative emotions. Two different composite scores can be computed to indicate positive and negative emotion regulation ability (Min = 16, Max = 112 for each score), with higher scores indicating a higher level of difficulty regulating positive or negative emotions.
Time frame: 0 weeks, 3 weeks
Emotion Regulation Self-Efficacy for Positive and Negative Emotions
The German version of the Regulatory Emotional Self-Efficacy-Revised (RESE-R) Scale (adapted from Caprara et al., 2008) consists of 10 items, rated on a 5-point scale (1 = not at all well to 5 = very well). The scale assesses self-efficacy in expressing positive emotions (4 items, Min = 1, Max = 5) and in managing negative emotions (despondency/distress: 3 Items, anger/irritation: 3 items, Min = 1, Max = 5), with higher scores indicating higher self-efficacy beliefs.
Time frame: 0 weeks, 3 weeks
Emotion Regulation Strategy Use in Positive and Negative Emotional Contexts
Data will be collected using an adaption of the smartphone app EmoTrack (adapted from Pruessner et al., 2023). The app assesses among other factors, the intensity with which participants employ various emotion regulation strategies to manage specific positive and negative emotions, using an 11-point scale (1 = not at all, 11 = very much). Scores for strategy usage will be aggregated across all intensity ratings from the four daily measurements over a continuous seven-day period (Min = 1, Max = 11). Higher scores indicate that a participant engages in a specific strategy more strongly in daily life.
Time frame: 0 weeks, 3 weeks
Depressive Symptoms
The Beck Depression Inventory-II (Wang et al., 2013) consists of 21 items, rated on a 4-point scale (0-3) with four statements of increasing severity related to a specific depressive symptom. Higher sum scores (Min = 0, Max = 63) indicate a higher severity of depressive symptoms.
Time frame: 0 weeks, 3 weeks
Positive and Negative Affect
Data will be collected using an adaption of the smartphone app EmoTrack (adapted from Pruessner et al., 2023). The app measures among other factors, the intensity of specific positive and negative emotions selected from the Positive and Negative Affect Schedule - Expanded Form (PANAS-X; Watson \& Clark, 1994), using an 11-point scale (1 = not at all, 11 = very much). Scores for positive and negative emotions will be aggregated across all intensity ratings from the four daily measurements over a continuous seven-day period (Min = 1, Max = 11). Higher scores indicate that participants experience a higher level of positive (resp. negative) emotions in daily life.
Time frame: 0 weeks, 3 weeks
Emotion Beliefs (Controllability, Usefulness) about Positive and Negative Emotions
The Emotion Beliefs Questionnaire (EBQ, Becerra et al., 2020) consists of 16 items, rated on a 7-point scale (1 = strongly disagree, 4 = neither agree nor disagree, 7 = strongly agree). Sum scores can be computed for different subscales: General-Contollability (8 Items, Min: 8; Max: 56), Positive-Usefulness (4 Items, Min: 4, Max: 28), Negative-Usefulness (4 Items, Min: 4, Max: 28), with higher scores indicating that people believe, that emotions are uncontrollable and useless.
Time frame: 0 weeks, 3 weeks
Well-being
The World Health Organization Well-Being Index (WHO-5; Topp et al., 2015) consists of 5 items, rated on a 6-point scale (0 = at no time, 5 = all of the time). Elevated scores indicate a higher well-being (Min = 0, Max = 25).
Time frame: 0 weeks, 3 weeks
Life Satisfaction
The Satisfaction With Life Scale (SWLS; Diener et al., 1985) comprises 5 items, rated on a 7-point scale (1 = strongly disagree to 7 = strongly agree). Higher scores indicate a higher level of life satisfaction (Min = 5, Max = 35).
Time frame: 0 weeks, 3 weeks
Emotion Beliefs about Positive Emotions (Delay Happiness, Living in the Moment)
The Delaying Happiness and Living in the Moment Scale (Park et al., 2021) consists of 2 subscales with 10 items each, rated on a 7-point scale (1 = strongly disagree to 7 = strongly agree). Higher values indicate stronger beliefs that happiness is an investment over time (Delay Happiness) or stronger beliefs that one should savor happiness now versus later (Living in the Moment, Min = 1, Max = 7 for each scale).
Time frame: 0 weeks, 3 weeks
Emotion Beliefs about Positive Emotions (Fear of Happiness)
The Fear of Happiness Scale (Joshanloo et al., 2014) consists of 5 items. Each item is measured on a 7-point scale (1 = strongly disagree to 7 = strongly agree). Higher scores indicate a greater fear of happiness (Min = 5, Max = 35).
Time frame: 0 weeks, 3 weeks
Negative Emotional Contrast Avoidance
The Contrast Avoidance Questionnaire-General (CAQ-GE; Llera et al., 2017) consists of 25 items, answered on a 5-point scale (1 = not at all true, 2 = slightly true, 3 = somewhat true, 4 = very true, and 5 = absolutely true), which are assigned to two subscales. Higher scores on the two subscales indicate a higher tendency to create and sustain negative emotions to avoid negative emotional contrasts (18 items, Min = 18, Max = 90) and more discomfort with emotional shifts (7 items, Min = 7, Max = 35).
Time frame: 0 weeks, 3 weeks
Emotion Regulation Strategy Use
The Heidelberg Form for Emotion Regulation Strategies (HFERST; Izadpanah et al., 2019) consists of 28 items that measure the habitual use of a range of emotion regulation strategies on a 5-point scale (1 = never, 2 = occasionally, 3 = about half the time, 4 = usually, 5 = always): rumination, avoidance, expressive suppression, experience suppression, reappraisal, social support, acceptance, and problem solving. Higher responses indicate a more frequent use of the specific emotion regulation strategy (Min = 1, Max = 5 for each scale).
Time frame: 0 weeks, 3 weeks
Self-Esteem
The Rosenberg Self-Esteem Scale (RSES; Roth et al., 2008) consists of 10 items, rated on a 6-point Likert scale (1 = strongly disagree to 6 = strongly agree). Higher score indicate a higher level of self-esteem (Min = 1, Max = 6).
Time frame: 0 weeks, 3 weeks
Locus of Control
The Internal-External Locus of Control-4 (IE-4; Niessen et al, 2022) Scale comprises 4 items, rated on a 5-point scale (1 = doesn't apply at all, 2 = applies a bit, 3 =applies somewhat, 4 = applies mostly, 5 = applies completely). The items can be allocated to two subscales: Internal Locus of Control (IL) and External Locus of Control (EL). Elevated scores on the Internal Locus of Control subscale signify a stronger belief in personal control over life events, whereas higher scores on the External Locus of Control subscale indicate a perception that events occur due to chance, fate, or the influence of powerful others
Time frame: 0 weeks, 3 weeks
Controllability Beliefs about Emotions
The Implicit Theories of Emotion Scale (Tamir et al., 2007) consists of 5 items, answered on a 5-point scale (1 = strongly disagree, 5 = strongly agree). Higher scores indicate that a person believes emotions are malleable and controllable (Min = 1, Max = 5).
Time frame: 0 weeks, 3 weeks
Anxiety Symptoms
The General Anxiety Disorder Scale (GAD-7; Spitzer et al., 2006) consists of 7 items, rated on a 4-point scale (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day). Scores range from 0 to 21, with higher scores indicating a higher severity of symptoms of generalized anxiety disorder.
Time frame: 0 weeks, 3 weeks
Plan to share: Yes — De-identified dataset
Supporting information: Statistical analysis plan, Analytic code
Time frame: Data will be made available after the publication of the study results.
Access criteria: Open access, available upon request.
Data sharing details ↗ · osf.io
Started Jan 2024 (actual). Primary completion is estimated for Aug 2025, 19 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 19 months is below that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.